MYRIAD

    

Myriad is a biopharmaceutical company focused on the development of novel healthcare products. In addition to an expanding preclinical pipeline, our drug discovery and development is strong in the areas of cancer and antivirals. We also develop and market predictive and personalized medicine products such as:
BRACAnalysis MELARIS COLARIS AP COLARIS
A genetic test for hereditary breast and ovarian cancer A genetic test for hereditary melanoma A genetic test for adenomatous polyposis syndromes A genetic test for hereditary nonpolyposis colorectal cancer (HNPCC)
TheraGuide 5-FU
A genetic test to
predict toxicity to 5-FU/capecitabine-based chemotherapy

Be Ready Against Cancer
7-Oct-2008 Myriad Genetics Acquires Novel Therapeutic Drug Management Technology From Saladax Biomedical
23-Sep-2008 MultiVu Video Feed: WOMEN WITH A HEREDITARY RISK OF BREAST AND OVARIAN CANCER ARE ENCOURAGED TO GET TESTED - THOSE WITH AN ALTERED BRCA1 OR BRCA2 GENE HAVE A 56 TO 87 PERCENT RISK TO DEVELOP BREAST CANCER BY AGE 70
17-Sep-2008 Myriad Genetics Announces Topline Results of Phase 1 Trial of Vivecon for HIV
© 2008 Myriad Genetics, Inc.